IPCALAB

Ipca Laboratories Share Price

₹1,566.70 +30.15 (1.96%)

18 Nov, 2024 22:18

SIP TrendupStart SIP in IPCALAB

Start SIP

Performance

  • Low
  • ₹1,507
  • High
  • ₹1,595
  • 52 Week Low
  • ₹1,041
  • 52 Week High
  • ₹1,709
  • Open Price₹1,544
  • Previous Close₹1,537
  • Volume376,265

Investment Returns

  • Over 1 Month -4.89%
  • Over 3 Month + 17.1%
  • Over 6 Month + 20.36%
  • Over 1 Year + 44.92%
SIP Lightning

Smart Investing Starts Here Start SIP with Ipca Laboratories for Steady Growth!

Invest Now

Ipca Laboratories Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.

  • P/E Ratio
  • 60.1
  • PEG Ratio
  • 1.8
  • Market Cap Cr
  • 39,748
  • P/B Ratio
  • 5.1
  • Average True Range
  • 50.42
  • EPS
  • 26.47
  • Dividend Yield
  • 0.3
  • MACD Signal
  • 7.02
  • RSI
  • 51.1
  • MFI
  • 60.47

Ipca Laboratories Financials

Ipca Laboratories Technicals

EMA & SMA

Current Price
₹1,566.70
+ 30.15 (1.96%)
pointer
  • stock-down_img
  • Bullish Moving Average 14
  • stock-up_img
  • Bearish Moving Average 2
  • 20 Day
  • ₹1,563.59
  • 50 Day
  • ₹1,526.68
  • 100 Day
  • ₹1,448.73
  • 200 Day
  • ₹1,336.03

Resistance and Support

1556.32 Pivot Speed
  • R3 1,693.13
  • R2 1,644.07
  • R1 1,605.38
  • S1 1,517.63
  • S2 1,468.57
  • S3 1,429.88

What's your outlook on Ipca Laboratories?

You can only vote for once

Ratings

Master Rating

EPS Strenth

Price Strength

Buyer Demand

Group Rank

Ipca Laboratories Ltd. is a global pharmaceutical company, producing over 350 formulations and 80 APIs. Operating in 120+ countries, it leads in therapeutic areas like pain, rheumatology, and antimalarials, with fully-automated facilities approved by global regulatory bodies.

Ipca Laboratories has an operating revenue of Rs. 8,533.40 Cr. on a trailing 12-month basis. An annual revenue growth of 23% is outstanding, Pre-tax margin of 11% is healthy, ROE of 8% is fair but needs improvement. The company has a reasonable debt to equity of 9%, which signals a healthy balance sheet. The stock from a technical standpoint is trading close to its 50DMA and comfortably placed above its 200DMA, around 16% above 200DMA. It needs to take support around the 50 DMA level to continue further upside move. From an O'Neil Methodology perspective, the stock has an EPS Rank of 68 which is a FAIR score but needs to improve its earnings, a RS Rating of 70 which is FAIR indicating the recent price performance, Buyer Demand at B+ which is evident from recent demand for the stock, Group Rank of 38 indicates it belongs to a strong industry group of Medical-Generic Drugs and a Master Score of B is close to being the best. Institutional holding has gone up in the last reported quarter is a positive sign. Overall, the stock definitely has some strength, you may want to examine it in more detail.

Disclaimer: This stock analysis report is algorithmically generated for informational purposes only and should not be considered as a buy or sell recommendation.

View More

Ipca Laboratories Corporate Actions - Bonus, Splits, Dividends

Date Purpose Remarks
2024-11-14 Quarterly Results & Interim Dividend
2024-09-30 Others
2024-08-13 Quarterly Results
2024-05-29 Audited Results & Final Dividend
2024-02-14 Quarterly Results
Date Purpose Remarks
2024-11-25 INTERIM Rs.2.00 per share(200%)Interim Dividend (Revised)
2023-11-22 INTERIM Rs.2.00 per share(200%)Interim Dividend (Revised)
2022-11-23 INTERIM Rs.4.00 per share(400%)Interim Dividend
2021-11-23 INTERIM Rs.8.00 per share(400%)Interim Dividend
Date Purpose Remarks
2022-01-11 Split Rs.0.00 split from Rs. 2/- to Re. 1/-.

Ipca Laboratories F&O

Ipca Laboratories Shareholding Pattern

46.3%
28.55%
4.87%
10.83%
0%
6.93%
2.52%

About Ipca Laboratories

  • NSE Symbol
  • IPCALAB
  • BSE Symbol
  • 524494
  • Managing Director
  • Mr. Ajit Kumar Jain
  • ISIN
  • INE571A01038

Similar Stocks to Ipca Laboratories

Ipca Laboratories FAQs

Ipca Laboratories share price is ₹1,566 As on 18 November, 2024 | 22:04

The Market Cap of Ipca Laboratories is ₹39747.8 Cr As on 18 November, 2024 | 22:04

The P/E ratio of Ipca Laboratories is 60.1 As on 18 November, 2024 | 22:04

The PB ratio of Ipca Laboratories is 5.1 As on 18 November, 2024 | 22:04

Open Free Demat Account

Be a part of 5paisa community - The first listed discount broker of India.

+91
 
footer_form

Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.

Q2FY23